Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Li, Hongjie ^a   Smolen, Gromoslaw A ^b   Beers, Lisa F ^a   Xia, Li ^c   Gerald, William ^d   Wang, Joanne ^c   Haber, Daniel A ^b   Lee, Sean Bong ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; GENE PRODUCT; RNA BINDING PROTEIN EWS; WT1 PROTEIN; ADENOSINE; PRIMER DNA; SLC29A4 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DESMOPLASTIC SMALL ROUND CELL TUMOR; GENE EXPRESSION; GENE FUNCTION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PH; PROTEIN TARGETING; TRANSCRIPTION INITIATION; DOSE RESPONSE; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ADENOSINE; BASE SEQUENCE; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; HUMANS; HYDROGEN-ION CONCENTRATION; PROMOTER REGIONS (GENETICS); PROTEIN TRANSPORT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN EWS; WT1 PROTEINS;

EID: 48649083822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002353     Document Type: Article

References (45)

1. Gerald WL, Ladanyi M, de Alava E, Cuatrecasas M, Kushner BH, et al. (1998) Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 16: 3028-3036.
2. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, et al. (1991) Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol 15: 499-513.
3. Lae ME, Roche PC, Jin L, Lloyd RV, Nascimento AG (2002) Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 26: 823-835.
4. Gerald WL, Haber DA (2005) The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol 15: 197-205.
5. Gerald WL, Rosai J, Ladanyi M (1995) Characterization or the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci U S A 92: 1028-1032.
6. Ladanyi M, Gerald W (1994) rusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 54: 2837-2840.
7. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
8. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L (1996) hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to die pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. Embo J 15: 5022-5031.
9. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. (1993) The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393-7398.
10. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, et al. (1994) The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 9: 3087-3097.
11. Li H, Watford W, Li C, Parmelee A, Bryant MA, et al. (2007) Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest 117: 1314-1323.
12. Azuma M, Embree LJ, Sabaawy H, Hickstein DD (2007) Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. PLoS ONE 2: e979.
13. Rivera MN, Haber DA (2005) Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 5: 699-712.
14. Lee SB, Haber DA (2001) Wilms tumor and the WT1 gene. Exp Cell Res 264: 74-99.
15. Reddy JC, Licht JD (1996) The WT1 Wilms'tumor suppressor gene: how much do we really know? Biochim Biophys Acta 1287: 1-28
16. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, et al. (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Prue Natl Acad Sci U S A 813: 9618-9622.
17. Rauscher FJ 3rd, Morris JF, Tournay OE, Cook DM, Curran T (1990) Binding of the Wilms' tumor locus zinc ringer protein to the EGR-1 consensus sequence. Science 250: 1259-1262.
18. Kim J, Lee K, Pelletier J (1998) The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct. Oncogene 16: 1021-1030.
19. Kim J, Lee K, Pelletier J (1998) The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties. Oncogene 16: 1973-1979.
20. Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, et al. (1997) The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet 17: 309-313.
21. Finkeltov I, Kuhn S, Glaser T, Idelman G, Wright JJ, et al. (2002) Transcriptional regulation of IGF-1 receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 21: 1890-1898.
22. Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, et al. (2002) Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene 21: 2009-2019.
23. Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, et al. (2002) Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell 2: 497-505.
24. Ito E, Honma R, Imai J, Azuma S, Kanno T, et al. (2003) A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round- cell tumor. Am J Pathol 163: 2165-2172.
25. Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, et al. (2003) Identification of a DNA-binding site and transcriptional target for the EWS-WTI(+KTS) oncoprotein. Genes Dev 17: 2094-2107.
26. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, et al. (2006) Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99: 510-519.
27. Xia L, Engel K, Zhou M, Wang J (2007) Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol 292: F682-690.
28. Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279: 50042-50049.
29. Baldwin SA, Beal PR, Yao, SY, King AE, Cass CE, et al. (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447: 735-743.
30. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, et al. (2002) Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1. Lab Invest 82: 1175-1182.
31. Elwi AN, Damaraju VL, Baldwin SA, Young JD, Sawyer MB, et al. (2006) Renal nucleoside transporters: physiological and clinical implications. Biochem Cell Biol 84: 844-858.
32. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, et al. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961.
33. Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, et al. (1996) Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 14: 1526-1531.
34. Morrison AA, Venables JP, Dellaire G, Ladomery MR (2006) The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. Biochem Cell Biol 84: 789-798.
35. Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, et al. (2006) The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron. Genes Dev 20: 1597-1608.
36. Baldwin SA, Yao, SY, Hyde RJ, Ng AM, Foppolo S, et al. (2005) Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280: 15880-15887.
37. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
38. Adair TH (2005) Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol 289: R283-R296.
39. Kong W, Engel K, Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5: 63-84.
40. Hoffman MA, Janson D, Rose E, Rai KR (1997) Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15: 1138-1142.
41. Saven A, Piro L (1994) Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 330: 691-697.
42. Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3: 415-424.
43. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, et al. (2007) Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 282: 16278-16287.
44. Liu SQ, Saijo K, Todoroki T, Ohno T (1995) Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med 1: 267-271.
45. Miret S, De Groene EM, Klaffke W (2006) Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J Biomol Screen 11: 184-193.